Format

Send to

Choose Destination
United European Gastroenterol J. 2017 Apr;5(3):380-388. doi: 10.1177/2050640616662432. Epub 2016 Jul 26.

Effects of conventional and a novel colonic-release bile acid sequestrant, A3384, on fibroblast growth factor 19 and bile acid metabolism in healthy volunteers and patients with bile acid diarrhoea.

Author information

1
Department of Gastroenterology, Imperial College London, Hammersmith Hospital, London, UK.
2
Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, Gothenburg, Sweden.
3
Albireo AB, Gothenburg, Sweden.
4
Division of Gastroenterology, Department of Internal Medicine Kärnsjukhuset, University of Göteborg, Skövde, Sweden.

Abstract

BACKGROUND:

Primary bile acid diarrhoea (BAD) is associated with increased bile acid synthesis and low fibroblast growth factor 19 (FGF19). Bile acid sequestrants are used as therapy, but are poorly tolerated and may exacerbate FGF19 deficiency.

AIM:

The purpose of this study was to evaluate the pharmacological effects of conventional sequestrants and a colonic-release formulation preparation of colestyramine (A3384) on bile acid metabolism and bowel function in patients with BAD.

METHODS:

Patients with seven-day 75selenium-homocholic acid taurine (SeHCAT) scan retention <10% were randomised in a double-blind protocol to two weeks treatment with twice-daily A3384 250 mg (n = 6), 1 g (n = 7) or placebo (n = 6). Thirteen patients were taking conventional sequestrants at the start of the study. Symptoms were recorded and serum FGF19 and 7α-hydroxy-4-cholesten-3-one (C4) measured.

RESULTS:

Median serum FGF19 on conventional sequestrant treatment was 28% lower than baseline values in BAD (p < 0.05). C4 on conventional sequestrant treatment was 58% higher in BAD (p < 0.001). No changes were seen on starting or withdrawing A3384. A3384 improved diarrhoeal symptoms, with a median reduction of 2.2 points on a 0-10 Likert scale compared to placebo, p < 0.05.

CONCLUSIONS:

Serum FGF19 was suppressed and bile acid production up-regulated on conventional bile acid sequestrants, but not with A3384. This colonic-release formulation of colestyramine produced symptomatic benefit in patients with BAD.

KEYWORDS:

Bile acid sequestrants; bile acid diarrhoea; bile acid malabsorption; chronic diarrhoea; colestyramine; fibroblast growth factor 19; irritable bowel syndrome

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center